D010880Chemicals & DrugsD03.383.62135610330.655799PiperidinesFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:meshTreeNumberMeSH tree numberprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:positionInDivisionposition in divisionprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierDepartmentDivisionvivo:hrJobTitleHR job titleInformation ResourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlevivo:researchAreaOfresearch area ofvivo:subjectAreaForsubject area forrdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonLeukemiaThoracic Head & Neck Medical OncologyMD AndersonWILLIAM GWIERDAWILLIAM G WIERDA8937WIERDA, WILLIAM GProfessorJOHN VICTORHEYMACHJOHN VICTOR HEYMACH9280HEYMACH, JOHN VICTORProfessorJAN ANDREASBURGERJAN ANDREAS BURGER9300BURGER, JAN ANDREASAssociate Professor74Professor10Assistant Professor14Associate Professor46Distinguished Emeritus Professor4.926510.00411928356research area of0.99470.00704286512subject area forDepartment of MedicineDepartment of NeurologyMedicine-General MedicineNeurologyBaylor College of MedicineRACHELLEDOODYRACHELLE DOODY0.000000000000000.000000000000002517DOODY, RACHELLEDistinguished Emeritus Professortrue1Distinguished Emeritus ProfessorDistinguished Emeritus ProfessorJORGECASTILLOJORGE CASTILLO18140CASTILLO, JORGEAssistant Professortrue1Assistant ProfessorAssistant Professor37985359Gordon MJ, Feng L, Strati P, Lee HJ, Hagemeister FB, Westin JR, Samaniego F, Marques-Piubelli ML, Vega Vazquez F, Parra Cuentas ER, Solis-Soto LM, Ma W, Wang J, Claret L, Averill B, Ibanez K, Fayad LE, Flowers CR, Green MR, Davis RE, Neelapu SS, Fowler NH, Nastoupil LJCancerSafety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study. Cancer. 2024 03 15; 130(6):876-885.Cancer2023-11-20T00:00:002023Safety and efficacy of ibrutinib in combination with rituximab and lenalidomide in previously untreated follicular and marginal zone lymphoma: An open label, phase 2 study.37955424Jain N, Croner LJ, Allan JN, Siddiqi T, Tedeschi A, Badoux XC, Eckert K, Cheung LWK, Mukherjee A, Dean JP, Szafer-Glusman E, Seymour JFClinical cancer research : an official journal of the American Association for Cancer ResearchAbsence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax. Clin Cancer Res. 2024 02 01; 30(3):498-505.Clin Cancer Res2024-02-01T00:00:002024Absence of BTK, BCL2, and PLCG2 Mutations in Chronic Lymphocytic Leukemia Relapsing after First-Line Treatment with Fixed-Duration Ibrutinib plus Venetoclax.38190628Herling M, Dearden C, Zaja F, El-Sharkawi D, Ding W, Bellido M, Khot A, Tick L, Jacobsen E, Eyre TA, Roos-Weil D, Kadia T, Lucchini E, Pflug N, Davids MS, Pena G, Mukherjee N, Badawi M, Vizkelety T, Staber PBBlood advancesLimited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study. Blood Adv. 2024 Feb 27; 8(4):842-845.Blood Adv2024-02-27T00:00:002024Limited efficacy for ibrutinib and venetoclax in T-prolymphocytic leukemia: results from a phase 2 international study.38184494Kang DW, Wang L, Short NJ, Ferrajoli A, Wang Y, Zhou S, Shen CPharmacoEconomicsCost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. Pharmacoeconomics. 2024 Apr; 42(4):409-418.Pharmacoeconomics2024-01-06T00:00:002024Cost Effectiveness of Zanubrutinib Versus Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia.38316517Callahan M, Amin A, Kaye FJ, Morse MA, Taylor MH, Peltola KJ, Sharma P, O'Reilly EM, Meadows Shropshire S, O'Brien S, Tschaika M, Le DTJournal for immunotherapy of cancerNivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032). J Immunother Cancer. 2024 Feb 05; 12(2).J Immunother Cancer2024-02-05T00:00:002024Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032).true1ProfessorProfessortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor